BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 18357751)

  • 1. [Virological and immunological bases for HIV-1 vaccine design].
    Yamamoto H; Matano T
    Uirusu; 2007 Dec; 57(2):133-9. PubMed ID: 18357751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-HIV adaptive immunity: determinants for viral persistence.
    Yamamoto H; Matano T
    Rev Med Virol; 2008; 18(5):293-303. PubMed ID: 18416450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytotoxic T lymphocytes specific for the simian immunodeficiency virus.
    Letvin NL; Schmitz JE; Jordan HL; Seth A; Hirsch VM; Reimann KA; Kuroda MJ
    Immunol Rev; 1999 Aug; 170():127-34. PubMed ID: 10566147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biphasic CD8+ T-Cell Defense in Simian Immunodeficiency Virus Control by Acute-Phase Passive Neutralizing Antibody Immunization.
    Iseda S; Takahashi N; Poplimont H; Nomura T; Seki S; Nakane T; Nakamura M; Shi S; Ishii H; Furukawa S; Harada S; Naruse TK; Kimura A; Matano T; Yamamoto H
    J Virol; 2016 Jul; 90(14):6276-6290. PubMed ID: 27122584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protection against chronic infection and AIDS by an HIV envelope peptide-cocktail vaccine in a pathogenic SHIV-rhesus model.
    Nehete PN; Chitta S; Hossain MM; Hill L; Bernacky BJ; Baze W; Arlinghaus RB; Sastry KJ
    Vaccine; 2001 Dec; 20(5-6):813-25. PubMed ID: 11738745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunization of macaques with live simian human immunodeficiency virus (SHIV) vaccines conferred protection against AIDS induced by homologous and heterologous SHIVs and simian immunodeficiency virus.
    Kumar A; Mukherjee S; Shen J; Buch S; Li Z; Adany I; Liu Z; Zhuge W; Piatak M; Lifson J; McClure H; Narayan O
    Virology; 2002 Sep; 301(2):189-205. PubMed ID: 12359422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of Complement-Mediated Lysis of Simian Immunodeficiency Virus (SIV) and SIV-Infected Cells Reveals Sex Differences in Vaccine-Induced Immune Responses in Rhesus Macaques.
    Miller-Novak LK; Das J; Musich TA; Demberg T; Weiner JA; Venzon DJ; Mohanram V; Vargas-Inchaustegui DA; Tuero I; Ackerman ME; Alter G; Robert-Guroff M
    J Virol; 2018 Oct; 92(19):. PubMed ID: 30021899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protection of rhesus monkeys against infection with minimally pathogenic simian-human immunodeficiency virus: correlations with neutralizing antibodies and cytotoxic T cells.
    Quinnan GV; Yu XF; Lewis MG; Zhang PF; Sutter G; Silvera P; Dong M; Choudhary A; Sarkis PT; Bouma P; Zhang Z; Montefiori DC; Vancott TC; Broder CC
    J Virol; 2005 Mar; 79(6):3358-69. PubMed ID: 15731230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination.
    Barouch DH; Santra S; Schmitz JE; Kuroda MJ; Fu TM; Wagner W; Bilska M; Craiu A; Zheng XX; Krivulka GR; Beaudry K; Lifton MA; Nickerson CE; Trigona WL; Punt K; Freed DC; Guan L; Dubey S; Casimiro D; Simon A; Davies ME; Chastain M; Strom TB; Gelman RS; Montefiori DC; Lewis MG; Emini EA; Shiver JW; Letvin NL
    Science; 2000 Oct; 290(5491):486-92. PubMed ID: 11039923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dominant induction of vaccine antigen-specific cytotoxic T lymphocyte responses after simian immunodeficiency virus challenge.
    Takahara Y; Matsuoka S; Kuwano T; Tsukamoto T; Yamamoto H; Ishii H; Nakasone T; Takeda A; Inoue M; Iida A; Hara H; Shu T; Hasegawa M; Sakawaki H; Horiike M; Miura T; Igarashi T; Naruse TK; Kimura A; Matano T
    Biochem Biophys Res Commun; 2011 May; 408(4):615-9. PubMed ID: 21531211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapid Development of gp120-Focused Neutralizing B Cell Responses during Acute Simian Immunodeficiency Virus Infection of African Green Monkeys.
    Amos JD; Himes JE; Armand L; Gurley TC; Martinez DR; Colvin L; Beck K; Overman RG; Liao HX; Moody MA; Permar SR
    J Virol; 2015 Sep; 89(18):9485-98. PubMed ID: 26157116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term control of simian immunodeficiency virus replication with central memory CD4+ T-cell preservation after nonsterile protection by a cytotoxic T-lymphocyte-based vaccine.
    Kawada M; Tsukamoto T; Yamamoto H; Takeda A; Igarashi H; Watkins DI; Matano T
    J Virol; 2007 May; 81(10):5202-11. PubMed ID: 17344296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequential immunization of macaques with two differentially attenuated vaccines induced long-term virus-specific immune responses and conferred protection against AIDS caused by heterologous simian human immunodeficiency Virus (SHIV(89.6)P).
    Kumar A; Lifson JD; Li Z; Jia F; Mukherjee S; Adany I; Liu Z; Piatak M; Sheffer D; McClure HM; Narayan O
    Virology; 2001 Jan; 279(1):241-56. PubMed ID: 11145906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes.
    Barouch DH; Kunstman J; Kuroda MJ; Schmitz JE; Santra S; Peyerl FW; Krivulka GR; Beaudry K; Lifton MA; Gorgone DA; Montefiori DC; Lewis MG; Wolinsky SM; Letvin NL
    Nature; 2002 Jan; 415(6869):335-9. PubMed ID: 11797012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Macaque models for AIDS vaccine development.
    Johnson RP
    Curr Opin Immunol; 1996 Aug; 8(4):554-60. PubMed ID: 8794019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Animal AIDS models].
    Ishii H; Matano T
    Nihon Rinsho; 2010 Mar; 68(3):423-7. PubMed ID: 20229784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms of protection against simian immunodeficiency virus infection.
    Johnson RP
    Vaccine; 2002 May; 20(15):1985-7. PubMed ID: 11983259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 25 years of HIV research! ... and what about a vaccine?
    Appay V
    Eur J Immunol; 2009 Aug; 39(8):1999-2003. PubMed ID: 19672891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Challenges and strategies for AIDS vaccine development.
    Oxford JS; Frezza P; Race E
    Vaccine; 1993; 11(6):612-4. PubMed ID: 8100664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Theory for prophylactic AIDS vaccine development].
    Nomura T; Matano T
    Uirusu; 2009 Dec; 59(2):267-75. PubMed ID: 20218335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.